MediWound Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MediWound stock.
View analyst ratings for MediWound or view top-rated stocks.

Wall Street analysts have given MediWound a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MediWound wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

MediWound saw a increase in short interest in the month of February. As of February 26th, there was short interest totaling 33,000 shares, an increase of 52.8% from the February 11th total of 21,600 shares. Based on an average daily trading volume, of 154,600 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the shares of the stock are short sold.
View MediWound's Short Interest.

MediWound is scheduled to release its next quarterly earnings announcement on Wednesday, May 19th 2021.
View our earnings forecast for MediWound.

MediWound Ltd. (NASDAQ:MDWD) issued its quarterly earnings data on Thursday, February, 25th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.05. The biopharmaceutical company had revenue of $6.67 million for the quarter, compared to the consensus estimate of $5.59 million. MediWound had a negative net margin of 53.12% and a negative trailing twelve-month return on equity of 94.63%.
View MediWound's earnings history.

MediWound's stock was trading at $2.31 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MDWD stock has increased by 128.6% and is now trading at $5.28.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued twelve-month target prices for MediWound's shares. Their forecasts range from $6.00 to $10.00. On average, they expect MediWound's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 42.0% from the stock's current price.
View analysts' price targets for MediWound or view top-rated stocks among Wall Street analysts.

Some companies that are related to MediWound include Canopy Rivers (RIV), Charlie's (CHUC), Natural Alternatives International (NAII), Nutra Pharma (NPHC), Happiness Biotech Group (HAPP), Glucose Health (GLUC), Mannatech (MTEX), True Drinks (TRUU), FSD Pharma (HUGE), Tauriga Sciences (TAUG), FitLife Brands (FTLF), Heyu Biological Technology (HYBT), Cyanotech (CYAN), GLG Life Tech (GLGLF) and Exactus (EXDI).
View all of MDWD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), The Blackstone Group (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDWD stock can currently be purchased for approximately $5.28.

MediWound has a market capitalization of $143.81 million and generates $31.79 million in revenue each year. The biopharmaceutical company earns $4.95 million in net income (profit) each year or $0.08 on an earnings per share basis.

MediWound employs 75 workers across the globe.

The official website for MediWound is www.mediwound.com.

MediWound is headquartered at 42 HAYARKON STREET, YAVNE L3, 8122745.

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]